Mitomycin-c Application for PRK

Mitomycin-c Application for Photorefractive Keratectomy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01504282

Enrollment

Registered

2012-01-05

Start date

Unknown

Completion date

Unknown

Last updated

2012-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Brief summary

To evaluate the safety and efficacy of 5 seconds mitomycin-C (MMC) application during photorefractive keratectomy (PRK) for patients with low myopia.

Interventions

DRUGmitomycin-C

DRUGPlacebo

balanced salt solution (BSS)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Inclusion criteria

* The inclusion criteria was ablation depth less than 65 µm, * a stable refractive error for at least 1 year * corrected distance visual acuity (CDVA) of 0.1 LogMAR or better.

Exclusion criteria

* Patients with keratoconus suspect, * excessive dry eyes, * impaired wound healing processes, * lenticular changes, * corneal dystrophy, * history of ocular surgery, * anterior or posterior uveitis, * glaucoma and retinal diseases were excluded.

Design outcomes

Primary

Measure	Time frame
Central corneal endothelial cell density (ECD) 6 months after the PRK	6 months

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026